

| Application no. | Drug | Applicant |
|-----------------|-------------------------------------------------------------------------------------|-----------------------------------------|
| ANDA 60-276 | Neomycin and Polymyxin B Sulfates and Bacitracin Ointment | Hance Brothers and White Co. |
| ANDA 60-422 | Tetracycline Hydrochloride Tablets | Premo Pharmaceutical Laboratories, Inc. |
| ANDA 62-362 | Erythromycin Estolate Suspension, 250 milligrams (mg) per 5 milliliters (mL). | Life Laboratories, Inc. |
| ANDA 80-126 | Isoniazid Tablets, 300 mg | Everylife. |
| ANDA 80-689 | Cyanocobalamin Injection, USP, 30 micrograms (µg) per mL, 100 µg/mL, and 100 µg/mL. | Dell Laboratories, Inc. |
| ANDA 83-387 | Lidocaine Hydrochloride Injection, USP, 1% | Do. |
| ANDA 83-388 | Lidocaine Hydrochloride Injection, USP, 2% | Do. |
| ANDA 83-665 | Vitamin A Capsules, USP | Wharton Laboratories. |
| ANDA 83-771 | Pyridoxine Hydrochloride Injection, USP, 50 mg/mL | Dell Laboratories, Inc. |
| ANDA 83-772 | Pyridoxine Hydrochloride Injection, USP, 100 mg/mL | Do. |
| ANDA 83-775 | Thiamine Hydrochloride Injection, USP, 100 mg/mL | Do. |
| ANDA 86-519 | Chlorpheniramine Maleate Tablets, USP, 4 mg | Newtron Pharmaceuticals, Inc. |
| ANDA 86-987 | Brompheniramine Maleate Tablets, USP, 4 mg | Do. |
| ANDA 87-791 | Fluorouracil Injection, 50 mg/mL | Marcher Laboratories, Ltd. |
| ANDA 88-871 | Hydrocodone Bitartrate and Acetaminophen, 5 mg/500 mg | Abana Pharmaceuticals, Inc. |
| ANDA 89-538 | Meprobamate Tablets, USP, 400 mg | K. M. Lee Laboratories. |

The Director, Center for Drug Evaluation and Research, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), and under authority of 21 CFR 5.82, finds that the holders of the applications listed above have repeatedly failed to submit reports required by § 314.81. Therefore, under this finding, approval of the applications listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 25, 1996.

Dated: August 25, 1996.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 96-24610 Filed 9-24-96; 8:45 am]

BILLING CODE 4160-01-F

Pesticide Residue Monitoring Data Base for Fiscal Year 1995; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of Fiscal Year (FY) 1995 pesticide residue monitoring data on computer diskettes. This is the fourth annual comprehensive compilation and public release of FDA monitoring data for pesticide residues in foods. The agency is making the information available on computer diskettes to facilitate its dissemination to interested persons.

ADDRESSES: Pesticide residue monitoring data on computer diskettes may be ordered from the National Technical Information Service (NTIS), U.S. Department of Commerce, 5285 Port Royal Rd., Springfield, VA 22161. Orders must reference NTIS order number PB96-503156 and include a payment of \$50.00 for each copy of the data base. In addition, there is a

handling fee of \$4.00 for one copy of the data base, \$6.00 for two copies, and \$8.00 for three or more copies. Payment may be made by check, money order, charge card (American Express, VISA, or MasterCard), or by billing arrangements made with NTIS. Charge card orders must include the charge account number and expiration date. For telephone orders or further information on placing an order call NTIS at 703-487-4650.

FOR FURTHER INFORMATION CONTACT:

Byron O. Bohannon, Center for Food Safety and Applied Nutrition (HFS-308), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-205-4152.

SUPPLEMENTARY INFORMATION: FDA is making available its FY 95 pesticide residue monitoring data as a set of three personal computer diskettes. The data base includes FDA pesticide monitoring coverage and findings for FY 95 by country/food product/pesticide combination. The data base is accompanied by a search program and report formats, written in dBase III+. Each year FDA receives numerous requests for these data. FDA has determined that it will facilitate dissemination of these data to interested persons if the agency provides for their general availability in a standardized diskette. A user's manual is provided that contains installation instructions and describes the structure and content of the data base.

Dated: September 19, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96-24611 Filed 9-24-96; 8:45 am]

BILLING CODE 4160-01-F

Indian Health Service

Submission for OMB review; Comment Request, Indian Health Service Loan Repayment Program

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Indian Health Service (IHS) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection activity was previously published in the Federal Register (61 FR 17903) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow 30 days for public comments to be submitted to the OMB. The IHS may not conduct or sponsor, and the respondent is not required to respond to any information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

PROPOSED COLLECTION: Title: Indian Health Service Loan Repayment Program (LRP). Type of Information Collection Request: A 3-year reinstatement with change of previously approved information collection 0917-0014, "Indian Health Service Loan Repayment Program." Need and Use of Information Collection: The information is needed to identify and select qualified health professionals to fill priority health professional vacancies at IHS health care facilities. The information collected is used to: evaluate applicant eligibility; rank and prioritize applicants by specialty; assign applicants to IHS health care facilities; determine payment amounts and schedules for paying the lending institutions; and, to provide data and statistics for program management